Skip to main content

09-05-2019 | Motor neuron diseases | Video

AAN 2019: Risdiplam potential for type 2, 3 SMA demonstrated

Laurent Servais presents the safety and exploratory efficacy data from the SUNFISH study evaluating the SMN2 pre‐mRNA splicing modifier risdiplam in individuals who have type 2 or 3 spinal muscular atrophy (4.33).

Funding for independent interviews at AAN 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits